• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Stephen Friend Berlin9 2011-11-10
 

Stephen Friend Berlin9 2011-11-10

on

  • 335 views

Stephen Friend, Nov 10, 2011. Berlin9, Washington, DC

Stephen Friend, Nov 10, 2011. Berlin9, Washington, DC

Statistics

Views

Total Views
335
Views on SlideShare
335
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Stephen Friend Berlin9 2011-11-10 Stephen Friend Berlin9 2011-11-10 Presentation Transcript

    • gd oi Nw nn o e ae w
    • Reality: Overlapping Pathways
    • The value of appropriate representations/ maps
    • WHY  NOT  USE     “DATA  INTENSIVE”  SCIENCE  TO  BUILD  BETTER  DISEASE  MAPS?  
    • what will it take to understand disease?                    DNA    RNA  PROTEIN  (dark  maHer)    MOVING  BEYOND  ALTERED  COMPONENT  LISTS  
    • 2002 Can one build a “causal” model?
    • (Eric Schadt)
    • We still consider much clinical research as if we we hunter gathers! not sharing - .
    • Clinical/genomic data are accessible but minimally usableLittle incentive to annotate and curate data for other scientists to use
    • Mathematicalmodels of disease are not built to be reproduced orversioned by others
    • Assumption that genetic alterationsin human conditions should be owned
    • Lack of standard forms for future rights and consentss
    • sharing as an adoption of common standards.. Clinical Genomics Privacy IP
    • Publication Bias- Where can we find the (negative) clinical data?
    • Sage Mission Sage Bionetworks is a non-profit organization with a vision to create a commons where integrative bionetworks are evolved by contributor scientists with a shared vision to accelerate the elimination of human diseaseBuilding Disease Maps Data RepositoryCommons Pilots Discovery Platform Sagebase.org
    • Sage Bionetworks Collaborators  Pharma Partners   Merck, Pfizer, Takeda, Astra Zeneca, Amgen, Johnson &Johnson  Foundations   Kauffman CHDI, Gates Foundation  Government   NIH, LSDF  Academic   Levy (Framingham)   Rosengren (Lund)   Krauss (CHORI)  Federation   Ideker, Califarno, Butte, Schadt 19
    • sage bionetworks synapse project Watch What I Do, Not What I Say Reduce, Reuse, Recycle My Other Computer is Amazon Most of the People You Need to Work with Don’t Work with You
    • M e ogn g ow gd oi Nnoi g e e own wgi A M S FOR MAP i   ow PLAT ow i nn i o g EW N RULES GOVERN
    • CTCAP  Clinical Trial Comparator Arm Partnership “CTCAP”Strategic Opportunities For Regulatory Science Leadership and Action FDA September 27, 2011
    • Shared clinical/genomic data sharing and analysis will maximize clinical impact and enable discovery•  Graphic  of  curated  to  qced  to  models  
    • Arch2POCM  Restructuring  the  PrecompePPve   Space  for  Drug  Discovery   How  to  potenPally  De-­‐Risk       High-­‐Risk  TherapeuPc  Areas  
    • The  FederaPon  
    • sage federation:model of biological age Faster Aging U M i l r i nnowS Slower Aging e Clinical Association -  Gender -  BMI g -  Disease Age Differential Genotype Association Gene Pathway Expression i i owoe o e U i nS B
    • Sage  Congress  Project   April  20  2012   RA   Parkinson’s   Asthma  (Responders  CompePPons)  
    • Actionable Cancer Network ModelsAnd Open Medical Information Systems